Equities research analysts expect Applied Genetic Technologies Corporation (NASDAQ:AGTC) to post ($0.09) earnings per share for the current quarter, Zacks reports. Two analysts have made estimates for Applied Genetic Technologies Corporation’s earnings, with the lowest EPS estimate coming in at ($0.13) and the highest estimate coming in at ($0.01). Applied Genetic Technologies Corporation reported earnings per share of $0.11 in the same quarter last year, which would suggest a negative year over year growth rate of 181.8%. The company is scheduled to report its next quarterly earnings report on Wednesday, February 14th.

According to Zacks, analysts expect that Applied Genetic Technologies Corporation will report full year earnings of ($1.14) per share for the current financial year, with EPS estimates ranging from ($2.45) to ($0.45). For the next year, analysts forecast that the firm will post earnings of ($1.62) per share, with EPS estimates ranging from ($2.17) to ($0.78). Zacks Investment Research’s EPS averages are a mean average based on a survey of sell-side analysts that cover Applied Genetic Technologies Corporation.

Applied Genetic Technologies Corporation (NASDAQ:AGTC) last posted its earnings results on Wednesday, September 13th. The biotechnology company reported ($0.18) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $0.22 by ($0.40). Applied Genetic Technologies Corporation had a negative return on equity of 2.86% and a negative net margin of 8.78%. The firm had revenue of $8.30 million for the quarter, compared to the consensus estimate of $12.39 million. During the same period in the prior year, the business earned $0.15 EPS. Applied Genetic Technologies Corporation’s quarterly revenue was down 31.4% compared to the same quarter last year.

Several research firms have commented on AGTC. Wedbush reissued an “outperform” rating and set a $9.00 target price on shares of Applied Genetic Technologies Corporation in a research report on Wednesday, November 8th. HC Wainwright reissued a “buy” rating and set a $8.00 target price on shares of Applied Genetic Technologies Corporation in a research report on Wednesday, November 8th. Zacks Investment Research cut shares of Applied Genetic Technologies Corporation from a “hold” rating to a “strong sell” rating in a research report on Tuesday, October 31st. Stifel Nicolaus dropped their target price on shares of Applied Genetic Technologies Corporation from $15.00 to $12.00 and set a “buy” rating on the stock in a research report on Thursday, September 14th. Finally, Cantor Fitzgerald dropped their target price on shares of Applied Genetic Technologies Corporation from $15.00 to $9.00 and set a “neutral” rating on the stock in a research report on Thursday, September 14th. Two analysts have rated the stock with a sell rating, one has issued a hold rating and five have given a buy rating to the company. The stock presently has an average rating of “Hold” and an average target price of $10.17.

Large investors have recently bought and sold shares of the stock. Wells Fargo & Company MN raised its holdings in shares of Applied Genetic Technologies Corporation by 1.1% in the 1st quarter. Wells Fargo & Company MN now owns 19,005 shares of the biotechnology company’s stock worth $131,000 after purchasing an additional 200 shares during the period. Trexquant Investment LP raised its holdings in shares of Applied Genetic Technologies Corporation by 3.2% in the 2nd quarter. Trexquant Investment LP now owns 20,000 shares of the biotechnology company’s stock worth $102,000 after purchasing an additional 611 shares during the period. Credit Suisse AG raised its holdings in shares of Applied Genetic Technologies Corporation by 10.9% in the 1st quarter. Credit Suisse AG now owns 27,110 shares of the biotechnology company’s stock worth $187,000 after purchasing an additional 2,662 shares during the period. Nine Chapters Capital Management LLC bought a new stake in shares of Applied Genetic Technologies Corporation in the 3rd quarter worth approximately $113,000. Finally, Virtu KCG Holdings LLC bought a new stake in shares of Applied Genetic Technologies Corporation in the 2nd quarter worth approximately $178,000. 54.86% of the stock is currently owned by institutional investors.

TRADEMARK VIOLATION WARNING: This piece of content was first published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this piece of content on another site, it was stolen and reposted in violation of US & international trademark & copyright legislation. The legal version of this piece of content can be viewed at https://www.thecerbatgem.com/2017/11/17/zacks-analysts-expect-applied-genetic-technologies-corporation-agtc-to-announce-0-09-earnings-per-share.html.

Applied Genetic Technologies Corporation (AGTC) traded up $0.15 during trading on Tuesday, hitting $3.95. 96,055 shares of the company’s stock traded hands, compared to its average volume of 169,744. Applied Genetic Technologies Corporation has a 1 year low of $3.25 and a 1 year high of $10.40.

Applied Genetic Technologies Corporation Company Profile

Applied Genetic Technologies Corporation is a clinical-stage biotechnology company. The Company develops gene therapy products designed to manage the lives of patients with severe diseases in ophthalmology. As of March 31, 2016, its product candidates included treatments for X-linked retinoschisis (XLRS), over two forms of achromatopsia (ACHM) and X-linked retinitis pigmentosa (XLRP).

Get a free copy of the Zacks research report on Applied Genetic Technologies Corporation (AGTC)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Applied Genetic Technologies Corporation (NASDAQ:AGTC)

Receive News & Stock Ratings for Applied Genetic Technologies Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Applied Genetic Technologies Corporation and related stocks with our FREE daily email newsletter.